Diverse mechanisms of Wnt activation and effects of pathway inhibition on proliferation of human gastric carcinoma cells

Oncogene

Volumn 30, Issue 8, 2011, Pages 956-966

  Asciutti, S ^a   Akiri, G ^a   Grumolato, L ^a   Vijayakumar, S ^a   Aaronson, S A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

catenin; c Myc; DNTCF4; gastric cancer

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; MITOGEN ACTIVATED PROTEIN KINASE; P21 ACTIVATED KINASE; PROTEIN KINASE B; SHORT HAIRPIN RNA; T CELL FACTOR PROTEIN; T CELL FACTOR PROTEIN 4; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GASTROINTESTINAL TUMOR; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; ONCOGENE C MYC; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STOMACH CARCINOMA; UPREGULATION;

CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; WNT PROTEINS;

EID: 79952002141     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.475     Document Type: Article

References (39)

1. Akiri G, Cherian MM, Vijayakumar S, Liu G, Bafico A, Aaronson SA. (2009). Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene 28: 2163-2172.
2. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. (1995). PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 270: 27489-27494.
3. Bafico A, Gazit A, Wu-Morgan SS, Yaniv A, Aaronson SA. (1998). Characterization of Wnt-1 and Wnt-2-induced growth alterations and signaling pathways in NIH3T3 fibroblasts. Oncogene 16: 2819-2825. (Pubitemid 28279349)
4. Bas PLW, Friedel N, Nico JDB, Hugo WT, Winand NMD. (2000). Genetic alterations involving exon 3 of the β-catenin gene do not play a role in adenocarcinomas of the esophagus. Int J Cancer 86: 533-537.
5. Bechard M, Dalton S. (2009). Subcellular localization of glycogen synthase kinase 3-β controls embryonic stem cell self-renewal. Mol Cell Biol 29: 2092-2104.
6. Caca K, Kolligs FT, Ji X, Hayes M, Qian J, Yahanda A et al. (1999). β- and γ-catenin mutations, but not E-cadherin inactivation, underlie T-cell factor/lymphoid enhancer factor transcriptional deregulation in gastric and pancreatic cancer. Cell Growth Differ 10: 369-376. (Pubitemid 29284178)
7. Clements WM, Wang J, Sarnaik A, Kim OJ, MacDonald J, Fenoglio-Preiser C et al. (2002). β-catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res 62: 3503-3506. (Pubitemid 34651399)
8. D'Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE et al. (2001). c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 7: 235-239.
9. Filali M, Cheng N, Abbott D, Leontiev V, Engelhardt JF. (2002). Wnt-3A/β-catenin signaling induces transcription from the LEF-1 promoter. J Biol Chem 277: 33398-33410. (Pubitemid 34984863)
10. Giardiello FM, Offerhaus GJ, Lee DH, Krush AJ, Tersmette AC, Booker SV et al. (1993). Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 34: 1394-1396. (Pubitemid 23293626)
11. Grabsch H, Takeno S, Noguchi T, Hommel G, Gabbert HE, Mueller W. (2001). Different patterns of β-catenin expression in gastric carcinomas: relationship with clinicopathological parameters and prognostic outcome. Histopathology 39: 141-149. (Pubitemid 34225040)
12. He T-C, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT et al. (1998). Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512. (Pubitemid 28425575)
13. Ikenoue T, Ijichi H, Kato N, Kanai F, Masaki T, Rengifo W et al. (2002). Analysis of the β-catenin/T-cell factor signaling pathway in 36 gastrointestinal and liver cancer cells. Jpn J Cancer Res 93: 1213-1220. (Pubitemid 36032984)
14. Jang JW, Boxer RB, Chodosh LA. (2006). Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis. Mol Cell Biol 26: 8109-8121. (Pubitemid 44631009)
15. Janssen K-P, Alberici P, Fsihi H, Gaspar C, Breukel C, Franken P et al. (2006). APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology 131: 1096-1109. (Pubitemid 44498698)
16. Jho EH, Zhang T, Domon C, Joo CK, Freund JN, Costantini F. (2002). Wnt/β-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 22: 1172-1183. (Pubitemid 34094853)
17. Kim J-S, Crooks H, Dracheva T, Nishanian TG, Singh B, Jen J et al. (2002). Oncogenic β-catenin is required for bone morphogenetic protein 4 expression in human cancer cells. Cancer Res 62: 2744-2748. (Pubitemid 34525754)
18. Kim S-E, Lee W-J, Choi K-Y. (2007). The PI3 kinase-Akt pathway mediates Wnt3a-induced proliferation. Cellular Signal 19: 511-518. (Pubitemid 46107802)
19. Kolligs FT, Kolligs B, Hajra KM, Hu G, Tani M, Cho KR et al. (2000). γ-Catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of β-catenin. Genes Dev 14: 1319-1331. (Pubitemid 30397076)
20. Michl P, Downward J. (2005). Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers. Z Gastroenterol, 1133-1139. (Pubitemid 41584815)
21. Morin PJ, Spa rks AB, Korinek V, Barker N, Clevers H, Vogelstein B et al. (1997). Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 275: 1787-1790.
22. Overman MJ. (2009). Recent advances in the management of adenocarcinoma of the small intestine. Gastrointest Cancer Res 3: 90-96.
23. Park K-S, Jeon SH, Kim S-E, Bahk Y-Y, Holmen SL, Williams BO et al. (2006). APC inhibits ERK pathway activation and cellular proliferation induced by RAS. J Cell Sci 119: 819-827.
24. Pfaffl MW. (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
25. Pumiglia KM, Decker SJ. (1997). Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc Natl Acad Sci USA 94: 448-452. (Pubitemid 27053653)
26. Rubin JS, Osada H, Finch PW, Taylor WG, Rudikoff S, Aaronson SA. (1989). Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc Natl Acad Sci USA 86: 802-806. (Pubitemid 19056244)
27. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. (1997). Stabilization of β-catenin by genetic defects in melanoma cell lines. Science 275: 1790-1792. (Pubitemid 27136716)
28. Shimizu M, Fukunaga Y, Ikenouchi J, Nagafuchi A. (2008). Defining the roles of β-catenin and plakoglobin in LEF/T-cell factor-dependent transcription using β-catenin/plakoglobin-null F9 cells. Mol Cell Biol 28: 825-835.
29. Slinker BK. (1998). The statistics of synergism. J Mol Cell Cardiol 30: 723-731.
30. Stampfer MR, Bartley JC. (1985). Induction of transformation and continuous cell lines from normal human mammary epithelial cells after exposure to benzo[a]pyrene. Proc Natl Acad Sci USA 82: 2394-2398. (Pubitemid 15064494)
31. Sunaga N, Kohno T, Kolligs FT, Fearon ER, Saito R, Yokota J. (2001). Constitutive activation of the Wnt signaling pathway by CTNNB1 (β-catenin) mutations in a subset of human lung adenocarcinoma. Genes Chromosomes Cancer 30: 316-321.
32. Suriano G, Vrcelj N, Senz J, Ferreira P, Masoudi H, Cox K et al. (2005). β-Catenin (CTNNB1) gene amplification: a new mechanism of protein overexpression in cancer. Genes Chromosomes Cancer 42: 238-246. (Pubitemid 40171188)
33. Teuliere J, Faraldo MM, Shtutman M, Birchmeier W, Huelsken J, Thiery JP et al. (2004). β-Catenin-dependent and -independent effects of d N-plakoglobin on epidermal growth and differentiation. Mol Cell Biol 24: 8649-8661. (Pubitemid 39245084)
34. Tomita H, Yamada Y, Oyama T, Hata K, Hirose Y, Hara A et al. (2007). Development of gastric tumors in ApcMin/+ mice by the activation of the β-catenin/Tcf signaling pathway. Cancer Res 67: 4079-4087. (Pubitemid 46815052)
35. Van Cutsem E, Dicato M, Arber N, Benson A, Cunningham D, Diaz-Rubio E et al. (2006). The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005. Ann Oncol 17: vi13-vi18.
36. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A et al. (2002). The (β)-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111: 241-250. (Pubitemid 35292444)
37. Vlahos CJ, Matter WF, Hui KY, Brown RF. (1994). A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269: 5241-5248.
38. Woo DK, Kim HS, Lee HS, Kang YH, Yang HK, Kim WH. (2001). Altered expression and mutation of β-catenin gene in gastric carcinomas and cell lines. Int J Cancer 95: 108-113. (Pubitemid 32187082)
39. Zhurinsky J, Shtutman M, Ben-Ze'ev A. (2000). Differential mechanisms of LEF/TCF family-dependent transcriptional activation by β-catenin and plakoglobin. Mol Cell Biol 20: 4238-4252.